Rubius Therapeutics to Participate in Jefferies Virtual London Healthcare Conference

Rhea-AI Summary

Rubius Therapeutics (Nasdaq:RUBY) announced that its CEO, Pablo J. Cagnoni, M.D., will present at the Jefferies Virtual London Healthcare Conference on November 17, 2020. The presentation is scheduled for 3:15 p.m. GMT/10:15 a.m. EST. A live audio webcast will be accessible on the company's website, with an archived replay available for 90 days post-event. Rubius specializes in genetically engineering red blood cells to create Red Cell Therapeutics™, aiming to treat cancer and autoimmune diseases through innovative cellular therapies.

CAMBRIDGE, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™, today announced that Pablo J. Cagnoni, M.D., president and chief executive officer, will present at the Jefferies Virtual London Healthcare Conference on Tuesday, November 17, 2020, at 3:15 p.m. GMT/10:15 a.m. EST.

A live audio webcast will be available within the Investors & Media section of the Rubius Therapeutics website. An archived replay will be accessible for 90 days following the event.

About Rubius Therapeutics

Rubius Therapeutics, Inc. (Nasdaq:RUBY) is a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™. The Company’s proprietary RED PLATFORM® genetically engineers and cultures Red Cell Therapeutics to create selective, potent and off-the-shelf allogeneic cellular therapies for the potential treatment of cancer and autoimmune diseases. Rubius’ initial product candidates are designed to activate and expand immune system function to fight cancer and modulate the immune system to induce tolerance for the treatment of autoimmune diseases. Rubius Therapeutics’ manufacturing site was recently named 2020 Top 5 Best Places to Work in Rhode Island among medium-sized companies by Providence Business News. For more information, visit www.rubiustx.com, follow us on Twitter or LinkedIn or like us on Facebook.

Contacts:

Investors
Lori Melançon, Vice President, Corporate Communications and Investor Relations
+1 (617) 949-5296
lori.melancon@rubiustx.com

Media
Marissa Hanify, Director, Corporate Communications
Marissa.hanify@rubiustx.com

Dan Budwick, 1AB
+1 (973) 271-6085
dan@1abmedia.com

FAQ

What is the date and time of Rubius Therapeutics' presentation at the Jefferies Virtual London Healthcare Conference?

Rubius Therapeutics will present on November 17, 2020, at 3:15 p.m. GMT/10:15 a.m. EST.

Where can I watch the Rubius Therapeutics conference presentation?

The presentation can be watched via a live audio webcast on the Rubius Therapeutics website.

How long will the archived presentation from Rubius Therapeutics be available?

The archived presentation will be accessible for 90 days following the event.

What is the focus of Rubius Therapeutics' research?

Rubius Therapeutics focuses on genetically engineering red blood cells to develop Red Cell Therapeutics™ for treating cancer and autoimmune diseases.

What recognition did Rubius Therapeutics' manufacturing site receive in 2020?

Rubius Therapeutics' manufacturing site was named one of the 2020 Top 5 Best Places to Work in Rhode Island among medium-sized companies.